

ASHOK SHARMA & ASSOCIATES CHARTERED ACCOUNTANTS

311, "DEEPSHIKHA",
8, RAJENDRA PLACE,
NEW DELHI - 110 008
PHONE - 2576 9764

INDEPENDENT AUDITOR'S REPORT

The Members of MEDICAMEN ORGANICS LIMITED Report on the Financial Statements

We have audited the accompanying Financial Statements of **MEDICAMEN ORGANICS LIMITED** ("the Company") which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss and the statement of Cash Flows Statement for the year ended on that date, and a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006, as amended ("AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the Profit & Loss and its Cash Flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Financial Statements.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and informing our opinion thereon, and we do not provide a separate opinion on these matters.

Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report and Annual Return, but does not include the Financial Statements and our auditors' report thereon.

Our opinion on the Financial Statements does not cover the Board Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.



Contd. 2...

If, based on the work we have performed, we conclude that there is a material misstatement in this other information; we are required to report that fact. In absence of any material or information in this regard, we have nothing to report on the same.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.

Contd.3...



However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by section 143 (3) of the Act, based on our audit we report that:
 - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
 - b. In our opinion proper books of account as required by law relating to preparation of the Financial Statements have been kept by the Company so far as it appears from our examination of those books;
 - c. The Balance Sheet, the Statement of Profit and Loss and the Statement of Cash Flow Statement dealt with by this Report are in agreement with the books of account for the purpose of preparation of these Financial Statements.
 - d. In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e. On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f. With respect to the adequacy of the internal financial controls with reference to Financial Statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to Financial Statements.
 - g. With respect to the other matter to be included in the Auditor's Report in accordance with Rule-11 of the Companies (Audit and Auditors) Rule, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i) The Company does not have any pending litigations.
 - ii) The Company did not have any long-term contracts including derivatives contracts.
 - iii) There were no amounts which required to be transferred by the Company to the Investor Education and Protection Fund.



Contd.4...

2. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143(11) of the Act, we give in 'Annexure B' a statement on the matters specified in paragraphs 3 and 4 of the Order.

For ASHOK SHARMA & ASSOCIATES
CHARTERED ACCOUNTANTS

(ADITYA CHOUDHARY)
PARTNER

MEMBERSHIP NO.: 528486

PLACE : NEW DELHI

DATE : 26/11/2021

UDIN - 22528486AAAAAX2754

"ANNEXURE A" TO THE INDEPENDANT AUDITORS' REPORT

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **MEDICAMEN ORGANICS LIMITED** ("the Company") as of March 31, 2021, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Contd...2...



Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For ASHOK SHARMA & ASSOCIATES
CHARTERED ACCOUNTANTS

(ADITYA CHOUDHARY)
PARTNER

MEMBERSHIP NO.: 528486

PLACE : NEW DELHI

DATE : 26/11/2021

UDIN - 22528486AAAAAX2754

"ANNEXURE B" TO THE INDEPENDANT AUDITORS' REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on Companies (Auditor's Report) Order, 2016 ('the Order) issued by the Central Government in terms of Section 143(11) of the Companies Act, 2013('the Act') of Medicamen Organics Limited ('the Company')

1. In respect of the Company's fixed assets:
 - a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
 - b) The Fixed Assets have been physically verified by the management in a phased manner, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
 - c) The title deeds of immovable properties are held in the name of the company. In respect of immovable properties been taken on lease and disclosed as fixed assets in the financial statements, the lease agreements are in the name of the Company.
2. a) The Management has conducted the physical verification of inventory at reasonable intervals.
 - b) The Company is maintaining proper records of inventory. There were no material discrepancies noticed on verification between the physical stocks and the book records.
3. The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (C) of the Order are not applicable to the Company and hence not commented upon.
4. In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 In respect of loans, investments, guarantees, and security as applicable.
5. The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable. However the Company has taken unsecured loan from a company covered in the Register maintained under section 189 of the Act, during the year the total amount received was Rs. 78,77,000/- and Rs.32,97,045/- was repaid during the year. The amount of Rs.4,24,44,306/- and Rs.4,70,24,261/- was outstanding at the beginning and end of the financial year respectively.
6. The cost records as required under section 148(1) of the Act and as explained by the management are not applicable to the company.
7. a) According to information and According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2021 for a period of more than six months from the date on when they become payable.
 - b) According to the information and explanation given to us, there are no dues of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute.

Contd...2...



8. In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of loans from financial institution, bank, Government and has not issued any debentures.
9. In our opinion and according to the information and explanations given to us, the Company has raised money by working capital term loan from bank during the year and applied for the purpose for which obtained. Further no moneys were raised during the year through follow up public offer.
10. In our opinion and according to the information and explanations given to us, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
11. In our opinion and according to the information and explanations given to us, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
12. The Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.
13. In our opinion and according to the information and explanations given to us the Company is in compliance with Section 177 and 188 of the Act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable standards.
14. According to the information and explanations given to us the company has not made preferential allotment shares during the year under review.
15. In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
16. In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934

For ASHOK SHARMA & ASSOCIATES
CHARTERED ACCOUNTANTS

(ADITYA CHOUDHARY)
PARTNER
MEMBERSHIP NO.: 528486

PLACE : NEW DELHI
DATE : 26/11/2021

UDIN-22528486AAAAAX2754

MEDICAMEN ORGANICS LIMITED

Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi - 110052

CIN : U74899DL1995PLC066416

BALANCE SHEET AS AT 31.03.2021

(Figures in Rupees)

	PARTICULARS	Note No.	Figures as at the end of	
			current reporting period	previous reporting period
I. EQUITY AND LIABILITIES				
1 Shareholders' funds				
(a) Share Capital	2		6,00,00,000	6,00,00,000
(b) Reserves and Surplus	3		1,36,04,395	1,10,83,838
			7,36,04,395	7,10,83,838
2 Share Application Money Pending Allotement			-	-
3 Non- current liabilities				
(a) Long-term borrowings	4		1,15,44,733	45,14,521
(b) Deferred Tax liabilities (Net)	5		27,32,359	22,41,791
(c) Long-term Provisions	6		19,64,415	14,01,078
			1,62,41,507	81,57,390
4 Current Liabilities				
(a) Short term borrowings	7		8,41,79,612	7,39,19,098
(b) Trade payables			-	-
(i) Outstanding dues of Micro and Small Enterprises			-	-
(ii) Outstanding dues of Creditors other than Micro and Small Enterprises	8		7,56,12,586	9,71,16,010
(c) Other current liabilities	9		42,03,111	74,07,138
(d) Short term provisions	10		13,95,734	4,68,162
			16,53,91,043	17,89,10,408
TOTAL			25,52,36,945	25,81,51,636
II ASSETS				
1. Non-current assets				
(a) Property, Plant & Equipment	11			
(i) Tangible assets			10,50,55,693	11,26,18,917
(ii) Intangible assets			1,26,184	1,46,019
(iii) Capital work-in-progress	12		-	6,14,765
(b) Deferred Tax Assets (Net)	13		-	-
(c) Long-term loans and advances	14		14,13,719	17,65,776
			10,65,95,596	11,51,45,477
2. Current assets				
(a) Inventories	15		2,66,08,351	4,36,51,107
(b) Trade receivables	16		7,52,90,853	5,52,17,401
(c) Cash and cash equivalents	17		90,14,641	80,58,684
(d) Short-term loans and advances	18		3,69,64,803	3,49,00,606
(e) Other current assets	19		7,62,701	11,78,361
			14,86,41,349	14,30,06,159
TOTAL			25,52,36,945	25,81,51,636
See accompanying notes to the financial statements	1-35			

As per our attached Report of Even Date

For Ashok Sharma & Associates

Chartered Accountants

For & on behalf of the Board of Directors

Aditya Choudhary

Partner

Membership No.: 528486

UDIN : 22522486AAAAA2754

Place : New Delhi

Date: 26-11-2021

For Medicamen Organics Ltd.

B.K. Gupta
Director

B.K. Gupta

Director

DIN:00032772

Ashutosh Gupta
Director

Ashutosh Gupta

Director

DIN:00039995

MEDICAMEN ORGANICS LIMITED
Registered Address: 10, Community Centre No 2, Ashok Vihar Phase II New Delhi - 110052
CIN : U74899DL1995PLC066416
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31.03.2021

	PARTICULARS	Note No.	Figures as at the end of	
			current reporting period	Previous reporting period
I	Revenue from operations:			
	Sale of Products/Services		25,04,70,618	31,48,58,157
			25,04,70,618	31,48,58,157
II	Other Income	20	1,91,571	8,94,349
III	Total Revenue (I + II)		25,06,62,189	31,57,52,506
IV	Expenses			
	Cost of Materials Consumed	21	15,30,10,842	21,74,98,476
	Purchase of Traded Goods		-	-
	Changes in inventories of finished goods, work in progress and Stock-in- trade	22	55,96,101	(19,17,292)
	Employee benefits expense	23	2,79,43,836	2,95,56,221
	Finance Costs	24	44,33,875	37,87,977
	Depreciation and amortization expense	11	78,43,838	77,31,114
	Other expense	25	4,79,02,109	5,70,41,762
	Total Expense		24,67,30,601	31,36,98,258
V	Profit before exceptional and extraordinary items and tax (III-IV)		39,31,588	20,54,248
VI	Exceptional Items		-	-
VII	Profit before extraordinary items and tax (V-VI)		39,31,588	20,54,248
VIII	Extraordinary items(Loss of Delhi allocated to both unts in the ratio of Turnover		-	-
IX	Profit before tax (VII-VIII)		39,31,588	20,54,248
X	Tax expense:			
	(1) Current tax		10,00,000	4,00,000
	(2) Deferred tax		4,90,568	6,30,645
	(3) Earlier Year(s)		-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)		24,41,020	10,23,603
XII	Profit/(Loss) for the period		24,41,020	10,23,603
XIII	Brought Forward Profit/(Loss) from Previous Year		19,37,844	8,60,500
XIV	Net Profit/(Loss) carried over to Balance Sheet		43,78,864	19,37,844
XV	Earnings per equity share:			
	(1) Basic		0.41	0.17
	(2) Diluted		0.41	0.17
	See accompanying notes to the financial statements	1-35		

As per our attached Report of Even Date

For Ashok Sharma & Associates

Chartered Accountants

Aditya Choudhary

Partner

Membership No.: 528486

UDIN : 22528486AAAAAX2754

Place : New Delhi

Date: 26-11-2021

For & on behalf of the Board of Directors

For Medicamen Organics Ltd.

B.K. Gupta

Director

B.K. Gupta

Director

DIN:00032772

Ashutosh Gupta

Director

Ashutosh Gupta

Director

DIN:00039995

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH 2021

Particulars	Figures as at the end of	
	current reporting period	previous reporting period
Cash flow from operating activities		
Net Profit/(Loss) after tax from continuing operations	24,66,815	10,23,603
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	-	-
Depreciation/amortization on continuing operation	78,43,838	77,31,114
Interest expense	44,33,875	37,87,977
Interest income	(1,23,999)	(1,53,044)
Adjustment for Deffered Tax	4,90,568	6,30,645
Operating profit before working capital changes	1,51,11,097	1,30,20,295
Movements in working capital :		
Increase/(decrease) in trade payables	(2,15,03,424)	1,40,67,273
Increase / (decrease) in long-term provisions	5,63,337	4,61,953
Increase / (decrease) in short-term provisions	9,27,572	(2,90,411)
Increase/(decrease) in other current liabilities	(32,04,027)	(27,03,930)
Decrease/(increase) in trade receivables	(2,00,73,452)	92,37,546
Decrease/(increase) in inventories	1,70,42,756	(59,56,576)
Decrease / (increase) in long-term loans and advances	3,52,057	(7,30,430)
Decrease / (increase) in short-term loans and advances	(20,64,197)	(1,11,81,718)
Decrease/(increase) in other current assets	4,15,660	(81,954)
Direct taxes paid (net of refunds)	-	-
Net cash flow from/ (used in) operating activities (A)	(1,24,32,621)	1,58,42,048
Cash flows from investing activities		
Purchase of fixed assets, including intangible assets and CWIP	3,53,986	(46,73,647)
Interest received	1,23,999	1,53,044
Net cash flow from/(used in) investing activities (B)	4,77,985	(45,20,603)
Cash flows from financing activities		
Proceeds from issuance of share capital	-	-
Share Application Money	-	-
Repayment of long-term borrowings	70,83,954	(60,48,065)
Proceeds from short-term borrowings	1,02,60,514	43,01,703
Interest paid	(44,33,875)	(37,87,977)
Net cash flow from/(used in) in financing activities (C)	1,29,10,593	(55,34,339)
Net increase/(decrease) in cash and cash equivalents (A + B + C)	9,55,957	57,87,106
Cash and cash equivalents at the beginning of the year (D)	80,58,684	22,71,578
Cash and cash equivalents at the end of the year (E)	90,14,641	80,58,684
Difference in above D and E	9,55,957	57,87,106

See accompanying notes to the financial statements

1-35

As per our attached Report of Even Date

For Ashok Sharma & Associates

Chartered Accountants

Aditya Choudhary

Partner

Membership No.: 528486

UDIN : 22528486AAAAAX 2757

Place : New Delhi

Date: 26-11-2021

For & on behalf of the Board of Directors

For Medicamen Organics Ltd.

B.K. Gupta

Director

DIN:00032772

Ashutosh Gupta

Director

DIN:00039995

MEDICAMEN ORGANICS LIMITED
10, Community Centre No.2, Ashok Vihar, Phase-II, Delhi-110 052

SCHEDULE FORMING PART OF THE BALANCE SHEET

Notes forming Part of Accounts

NOTE '1':

(i) SIGNIFICANT ACCOUNTING POLICIES

General: The Accounts are prepared on the historical cost basis and on the accounting principle of going concern. All expenses and incomes to the extent considered payable and receivable respectively unless stated otherwise, have been accounted for on mercantile basis. Accounting Policies not specifically referred to otherwise are consistent and in accordance with generally accepted accounting principles.

Fixed assets: The gross block of fixed assets is stated at historical cost which includes duties and taxes.

Depreciation: Depreciation is provided on straight line method at the rates and manners specified in schedule II of the Companies Act, 2013 on fixed assets used for the purpose of business.

Foreign Exchange Transactions: Transactions in foreign currencies are recorded at the rate of exchange in force at the date of transaction. Receivables and Liabilities (considered good), in foreign currency at the year end, are converted at the rate of exchange prevailing at the end of financial year. Export sales are accounted for at the time of dispatch of the material from the factory for export.

Export Benefits: Export benefits are provided on accrual basis on satisfaction of condition relevant to the same.

(ii) The closing stock as on 31st March, 2021 is as taken, valued and certified by the management.

- Raw Material, Packing Material and Finished Goods are valued at cost or net realisable value whichever is lower.
- Work in Progress are valued at estimated cost
- Stores and Spares are valued at cost.

(iii) The Company has provided Employees Benefits as per the Accounting Standard-15 issued by the Institute of Chartered Accountants of India. Provision for Gratuity and Leave Encashment have been made in the books of accounts on the basis of actuarial valuation using the Project Unit Credit Method.

(iv) Company has made provision for deferred tax effect on the difference of depreciation between the amount, as per Income tax rules and profit & loss account for the year and accumulated retirement benefit provided for during the year.



For MEDICAMEN ORGANICS LTD.

Signature
Director

For MEDICAMEN ORGANICS LTD.

Signature
Director

NOTES FORMING PART OF ACCOUNTS

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '2'

SHARE CAPITAL

-Authorised

60,00,000 Equity Shares of Rs.10/- each

[Previous Year : 60,00,000 Equity Shares of Rs.10/- each]

6,00,00,000

6,00,00,000

-Issued, Subscribed and Paid up

60,00,000 Equity Shares of Rs.10/- each

fully paid-up.

[Previous Year : 60,00,000 Equity Shares of Rs.10/- each]

6,00,00,000

6,00,00,000

TOTAL

6,00,00,000

6,00,00,000

- Reconciliation of Shares:

	Nos	Amt(Rs)	Nos	Amt(Rs)
Opening Share Capital	60,00,000	6,00,00,000	60,00,000	6,00,00,000
Add: Shares issued During the year	-	-	-	-
Add: Bonus Shares Issued	-	-	-	-
Total	60,00,000	6,00,00,000	60,00,000	6,00,00,000
Less: Buy back of Shares	-	-	-	-
Less Reduction in Capital	-	-	-	-
Closing Share Capital	60,00,000	6,00,00,000	60,00,000	6,00,00,000

-List of Share holders having 5% or more Shares (In Nos)

Name Of Shareholders	In Nos	In %	In Nos	In %
1. Bal Kishan Gupta	44,86,650	75	44,86,650	75
2. Ashutosh Gupta	6,19,500	10	6,19,500	10
3. Shivani Chopra	6,00,000	10	6,00,000	10



For MEDICAMEN ORGANICS LTD.

Signature
Director

For MEDICAMEN ORGANICS LTD.

Signature
Director

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '3'		
RESERVES AND SURPLUS		
Capital Reserve	-	-
Securities Premium	91,44,283	91,44,283
Profit and Loss Account		
Opening Balance	19,39,554	8,62,210
Add: Adjustment of Provision of Taxation	79,538	53,742
Add: Profit/(Loss) During The Year	24,41,020	10,23,603
Balance	44,60,112	19,39,555
Less: Bonus Shares Issued	-	-
Less: Fixed Assets Written Off	-	-
Closing Balance	44,60,112	19,39,555
TOTAL	1,36,04,395	1,10,83,838

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '4'		
LONG TERM BORROWINGS		
-Secured		
Term Loans		
-From Bank		
Term Loan from Axis Bank Ltd	1,15,44,733	39,96,303
Secured by way of :		
i) First Charge on entire Fixed Assets and Current Assets of the Company both present and future including Land & Building situated at Plot No.60 & 61,Sector-6A,Sidcul,Hardwar		
ii) Personal Guarantee of two Directors		
Term Loan from ICICI Bank Ltd. (Vehicle Loan)	-	5,18,218
[Secured by way of Hypothecation of vehicles]		
[Repayable in 60 Instalments started from 01.06.2016 and last instalment due on 01.05.2021 EMI of Rs.46043/-]		
TOTAL	1,15,44,733	45,14,521



For MEDICAMEN ORGANICS LTD.

Sushil
Director

For MEDICAMEN ORGANICS LTD.

Abhishek
Director

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '5'

DEFERRED TAX LIABILITY

Deferred Tax Liabilities (Net)	27,32,359	22,41,791
TOTAL	27,32,359	22,41,791

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '6'

LONG TERM PROVISIONS

Provision For Employee Benefits

- Gratuity	15,81,437	10,92,984
- Leave Encashment	3,82,978	3,08,094

TOTAL	19,64,415	14,01,078
--------------	------------------	------------------

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '7'

SHORT TERM BORROWINGS

Loans repayable on demand

-Secured

Working Capital Loan from Axis Bank Ltd

3,71,55,351	3,14,74,792
-------------	-------------

Secured by way of :

- i) First Charge on entire Fixed Assets and Current Assets of the Company both present and future including Land & Building situated at Plot No.60 & 61,Sector-6A,Sidcul,Hardwar
- ii) Personal Guarantee of two Directors

-Unsecured

Unsecured Loans

From Directors

4,70,24,261	4,24,44,306
-------------	-------------

TOTAL	8,41,79,612	7,39,19,098
--------------	--------------------	--------------------



For MEDICAMEN ORGANICS LTD.

Singh
Director

For MEDICAMEN ORGANICS LTD.

Ashtutosh
Director

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '8'		
TRADE PAYABLES		
Trade Payables		
For Goods	6,65,49,157	8,73,50,826
For Expenses	35,32,876	67,41,812
Others		
Expenses Payables	55,30,553	30,23,372
TOTAL	<u>7,56,12,586</u>	<u>9,71,16,010</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '9'		
OTHER CURRENT LIABILITIES		
Creditors for Capital Goods/Expenses	-	1,16,043
Statutory Dues	9,37,643	7,51,410
Current maturities of long term debt	1,71,885	42,72,277
Deposits- Security Deposits	-	-
Interest Accrued and Due on Borrowings	-	-
Interest Accrued but not Due on Borrowings	-	-
Income received in Advance	-	-
Any Other Current Liability	30,93,583	22,67,408
TOTAL	<u>42,03,111</u>	<u>74,07,138</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	--	---

NOTE '10'
SHORT TERM PROVISIONS

Provision for Employee Benefits

- Leave Encashment	28,321	23,868
- Gratuity	29,108	19,178
- Bonus	3,38,305	25,116
Other Provisions:		
- Provision for Taxation	10,00,000	4,00,000
TOTAL	<u>13,95,734</u>	<u>4,68,162</u>



For MEDICAMEN ORGANICS LTD.

Signature
Director

For MEDICAMEN ORGANICS LTD.

Signature
Director

Note:11 Schedule of Tangible Assets
As on 31.03.2021

(All Fig. in Rs.)

GROSS BLOCK				DEPRECIATION BLOCK				NET BLOCK			
Description	Gross Value as on 01/04/2020	Addition during the Year	Disposal during the Year	Gross Value as on 31/03/2021	Depreciation as on 01/04/2020	Fixed Asset Written of	Deprecion during the Year	Adjustment during the period	Total as on 31/03/2021	W.D.V. as on 31/03/2021	W.D.V. as on 31/03/2020
Land-Hardwar	53,70,929	-	-	53,70,929	6,42,094	-	59,677	-	7,01,771	46,69,158	47,28,835
Building	4,78,35,794	-	-	4,78,35,794	84,79,832	-	15,14,816	-	99,94,648	3,78,41,146	3,93,55,962
Plant & Machinery	5,62,40,896	-	-	5,62,40,896	1,54,35,607	-	26,69,283	-	1,81,04,890	3,81,36,006	4,08,05,289
Machinery	2,52,259	-	-	2,52,259	1,81,705	-	11,587	-	1,93,292	58,967	70,554
Electrical Install.	71,21,887	-	-	71,21,887	43,38,162	-	3,78,397	-	47,16,559	24,05,328	27,83,725
A.C Plant	1,53,39,745	21,094	33,200	1,53,27,639	66,74,567	-	9,71,166	9,656	76,36,077	76,91,562	86,65,178
Office Equipment	4,31,663	1,15,169	-	5,46,832	3,76,890	-	13,026	-	3,89,916	1,56,916	54,773
Computer	12,27,256	81,780	-	13,09,036	7,42,544	-	2,83,015	-	10,25,559	2,83,477	4,84,712
Furniture & Fix.	29,36,038	-	-	29,36,038	5,75,203	-	2,74,469	-	8,49,672	20,86,366	23,60,835
Generator Set	20,62,570	-	-	20,62,570	9,41,766	-	1,30,631	-	10,72,397	9,90,173	11,20,804
Lab Equipments	78,75,617	66,280	-	79,41,897	19,99,436	-	6,61,209	-	26,60,645	52,81,252	58,75,181
Lift	27,61,191	-	-	27,61,191	6,38,737	-	1,74,876	-	8,13,613	19,47,578	21,22,454
Misc Fixed Assets	34,248	-	-	34,248	20,732	-	1,628	-	22,360	11,888	13,516
Other Machinerries	21,500	-	-	21,500	13,061	-	1,022	-	14,083	7,417	8,439
Water Pump	35,56,708	-	-	35,56,708	5,30,140	-	2,35,997	-	7,66,137	27,90,571	30,26,568
Car	42,66,232	-	-	42,66,232	31,25,227	-	4,43,204	-	35,68,431	6,97,801	11,41,005
Cycle	1,750	-	-	1,750	1,662	-	-	-	1,662	88	88
Total	15,73,36,283	2,84,323	33,200	15,75,87,406	4,47,17,365	-	78,24,003	9,656	5,25,31,713	10,50,55,693	11,26,18,918
Prev. Year	15,33,17,111	47,07,467	6,88,294	15,73,36,284	3,76,56,577	-	77,24,876	6,64,087	4,47,17,366	11,26,18,918	11,56,60,534

Note:11 Schedule of Intangible Assets
As on 31.03.2021

(All Fig. in Rs.)											
GROSS BLOCK					DEPRECIATION BLOCK					NET BLOCK	
Description	Gross Value as on 01/04/2020	Addition during the Year	Disposal during the Year	Gross Value as on 31/03/2021	Depreciation as on 01/04/2020	Fixed Asset Written of	Depreciation during the Year	Adjustment during the period	Total as on 31/03/2021	W.D.V. as on 31/03/2021	W.D.V. as on 31/03/2020
Patent/Trademark	8,00,700	-	-	8,00,700	6,54,681	-	19,835	-	6,74,516	1,26,184	1,46,019
Total	8,00,700	-	-	8,00,700	6,54,681	-	19,835	-	6,74,516	1,26,184	1,46,019
Prev. Year	7,91,700	9,000	-	8,00,700	6,40,568	-	14,113	-	6,54,681	1,46,019	1,51,132

For MEDICAMEN ORGANICS LTD.

For MEDICAMEN ORGANICS LTD.

Director

Director



Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '12'

CAPITAL WORK IN PROGRESS (Pending Capitalisation)

Advances To Suppliers	-	6,14,765
Less: transferred to Fixed Assets	-	-
	-	6,14,765

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '13'

DEFERRED TAX ASSETS

Deferred Tax Assets (Net)	-	-
TOTAL	-	-

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '14'

LONG TERM LOANS AND ADVANCES

Secured Considered Good:

Capital Advances	-	-
Security Deposits	-	-
Loans and Advances to Related Parties	-	-
Other Loans and Advances (Specify Nature)	-	-

Unsecured Considered Good:

Security Deposits	14,13,719	17,65,776
-------------------	-----------	-----------

Doubtful:

Capital Advances	-	-
Security Deposits	-	-
Loans and Advances to Related Parties	-	-
Other Loans and Advances (Specify Nature)	-	-

TOTAL	14,13,719	17,65,776
--------------	------------------	------------------

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	---	--

NOTE '15'

INVENTORIES

Raw Material	1,27,03,903	2,02,97,990
Packing Material	1,07,59,017	1,46,11,586
Work In Process	23,69,565	32,94,862
Finished Goods	7,25,408	53,23,190
Stock-in-Trade	-	-
Stores and Spares	50,458	1,23,480
Goods in Transit	-	-
TOTAL	2,66,08,351	4,36,51,107



For MEDICAMEN ORGANICS LTD.

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

[Signature]
Director

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '16'		
TRADE RECEIVABLES		
<i>Unsecured, Considered Good</i>		
Over Six Months		
Good	22,45,800	17,06,826
Doubtful	-	-
Below Six Months		
Good	7,30,45,053	5,35,10,575
Doubtful	-	-
Less:		
Provision for Doubtful Debts	-	-
	7,52,90,853	5,52,17,401
	<u>7,52,90,853</u>	<u>5,52,17,401</u>
	<u>7,52,90,853</u>	<u>5,52,17,401</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '17'		
CASH AND CASH EQUIVALENTS		
A. BALANCES WITH BANK		
- Balance with Banks		
-In Current Accounts	60,18,259	54,87,045
-In Fixed Deposit Accounts		
- As Margin Money with Bank	15,98,066	15,42,588
- Other Deposit	-	-
	76,16,325	70,29,633
- Other Bank Balances		
-In Fixed Deposit with more than 12 months maturity		
- As Margin Money with Bank	-	-
- Other Deposit	-	-
	-	-
- Cash on Hand	13,98,316	10,29,051
TOTAL	<u>90,14,641</u>	<u>80,58,684</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '18'		
SHORT TERM LOANS AND ADVANCES		
Others		
Advance for Capital Expenses	-	-
Advances to Suppliers	-	-
Prepaid Expenses	9,99,172	7,27,104
Advances Staff and Others	-	23,000
Earnest Money Deposit	11,09,614	11,05,908
Balance with Statutory Authorities	3,48,56,017	3,30,44,594
TOTAL	<u>3,69,64,803</u>	<u>3,49,00,606</u>



For MEDICAMEN ORGANICS LTD For MEDICAMEN ORGANICS LTD

Director

Director

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '19'		
OTHER CURRENT ASSETS		
Other Current Asset	7,62,701	11,78,361
	<u>7,62,701</u>	<u>11,78,361</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '20'		
OTHER INCOME		
Interest	1,23,999	1,53,044
Duty Drawback Received	-	47,300
Foreign Exchange Rate Difference	-	6,49,746
Other non-operating income (net of expenses)	67,572	1,427
Amount Written Off	-	42,832
TOTAL	<u>1,91,571</u>	<u>8,94,349</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
NOTE '21'		
COST OF MATERIAL CONSUMED		
Raw Material Consumed		
Opening Stock	2,02,97,989	1,60,65,025
Add: Purchases	11,28,80,851	16,33,43,848
	<u>13,31,78,840</u>	<u>17,94,08,873</u>
Less : Closing Stock	1,27,03,903	2,02,97,990
	<u>12,04,74,937</u>	<u>15,91,10,883</u>
Packing Material Consumed		
Opening Stock	1,46,11,585	1,48,05,266
Add: Purchases	2,86,83,337	5,81,93,913
Design and Development	-	-
	<u>4,32,94,922</u>	<u>7,29,99,179</u>
Less : Closing Stock	1,07,59,017	1,46,11,586
	<u>3,25,35,905</u>	<u>5,83,87,593</u>
TOTAL COST OF MATERIAL CONSUMED	<u>15,30,10,842</u>	<u>21,74,98,476</u>
Less: Sample Sale	-	-
NET-COST OF MATERIAL CONSUMED	<u>15,30,10,842</u>	<u>21,74,98,476</u>

For MEDICAMEN ORGANICS LTD.

[Signature]

Director

For MEDICAMEN ORGANICS LTD.

[Signature]

Director



Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	--	---

NOTE '22'

Changes in Inventory of Finished Goods and Work in Process

Opening Stock

Work-in Process	32,94,862		44,89,569	
Finished Goods	53,23,190		22,11,191	
Stock In Trade	<u>1,23,480</u>	87,41,532	<u>1,23,480</u>	68,24,240

Less : Closing Stock

Work-in-Process	23,69,565		32,94,862	
Finished Goods	7,25,408		53,23,190	
Stock In Trade	<u>50,458</u>	31,45,431	<u>1,23,480</u>	87,41,532

Stock Decreased /(Increased) by		<u>55,96,101</u>		<u>(19,17,292)</u>
-----------------------------------	--	------------------	--	--------------------

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	--	---

NOTE '23'

EMPLOYEE BENEFITS EXPENSES

Salaries & Allowances	2,01,26,731	2,03,17,872
Contribution to P.F and E.S.I.C.	11,23,524	15,22,528
Workmen and Staff Welfare Expenses	19,84,978	39,95,944
Directors Remuneration	<u>47,08,603</u>	<u>37,19,877</u>
TOTAL	<u>2,79,43,836</u>	<u>2,95,56,221</u>

Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	--	---

NOTE '24'

FINANCE COSTS

Interest Expense

Interest on Term Loan	18,23,243	15,50,378
Interest on Working Capital	24,64,104	20,96,098
Interest on Car Loan	31,968	80,384
Interest Others	<u>1,14,560</u>	<u>61,117</u>

TOTAL	<u>44,33,875</u>	<u>37,87,977</u>
--------------	------------------	------------------

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

For MEDICAMEN ORGANICS LTD.

[Signature]
Director



Particulars	Figures as at the end of current reporting period	Figures as at the end of previous reporting period
-------------	--	---

NOTE '25'

OTHER EXPENSES

Manufacturing Expenses

Labour Charges	1,07,86,822	1,65,58,924
Power, Fuel & Water	91,16,150	1,19,94,656
Consumable Stores	19,78,915	27,13,423
Freight & Cartage Inwards	19,39,304	23,10,566
Analysis & Testing Charges	18,45,134	42,16,226
Laboratories Expenses	6,50,443	8,21,663
Effluent Treatment Expenses	2,08,514	1,79,952
Repair & Maintainance		
-Building	62,291	1,45,107
-Machines & Electricals	21,10,199	27,28,826
-Others	3,66,619	2,36,133
TOTAL "A"	2,90,64,391	4,19,05,476

Administrative, Selling & Other Expenses

Legal & Professional Charges	25,14,190	27,90,310
Security Services Charges	19,38,842	18,50,980
Registration Charges	2,39,700	4,00,461
Bank Charges	3,08,497	8,00,321
Travelling & Conveyance	7,76,372	18,04,385
Fee & Subscription	3,13,820	3,44,307
Miscellaneous Expenses	12,85,575	19,50,357
Amount Written Off	34,59,221	-
Rates & Taxes	-	24,619
House Keeping Expenses	5,96,198	11,96,841
Communication Expenses	3,85,284	5,22,151
Printing & Stationery	2,95,033	4,74,876
Vehicle Running Expenses	16,120	2,02,444
Distribution Expenses	21,55,876	-
Commission On Sale	33,90,388	1,06,000
Computer Expenses	3,22,803	1,11,729
Office Expenses	-	34,118
Business Promotion Expenses	35,800	6,39,960
Freight & Cartage Outward	5,848	12,83,355
Packing & Forwarding	-	79,800
Insurance		
-- Vehicals	57,204	38,470
--Stocks & Building	3,07,172	-
-- Others	15,975	52,317
Rent	2,17,800	2,28,485
Auditors' Remuneration		
Audit Fees	2,00,000	1,50,000
Out of Pocket	-	50,000
TOTAL "B"	1,88,37,718	1,51,36,286
TOTAL "A+B"	4,79,02,109	5,70,41,762



For MEDICAMEN ORGANICS LTD. For MEDICAMEN ORGANICS LTD.

Director

Director

NOTE `26`: Details of Export

Value of Exports Calculated on F.O.B. basis* (Based on shipping Bills)	Nil (Rs. 32,78,903.72)
---	---------------------------

* Excluding Domestic Sales for Export against LUT

NOTE `27`:

The outstanding balances as on March 31, 2021 in respect of parties are subject to Verification.

NOTE `28`:

Earnings Per Share (EPS) – The numerator and denominator used to calculate Basic and Diluted Earnings per Share:

Particulars	31.03.2021	31.03.2020
Net Profit/(Loss) After Tax (Rs.)	24,41,020	10,23,603
Equity Shares (Nos.)	60,00,000	60,00,000
Nominal Value of Equity Share (Rs.)	10.00	10.00
Earnings Per Share Basic (Rs.)	0.41	0.17
Earnings Per Share Diluted (Rs.)	0.41	0.17

NOTE `29`:

Information required to be disclosed under Micro, Small and Medium Enterprises Development Act, 2006 has not been provided by any party dealing with the Company and accordingly no information for the same can be provided. The Company is otherwise generally regular in making payments as per terms except for special reasons.

NOTE `30`:

Contingent Liabilities: In the opinion of the Board of Directors, adequate provisions have been made in the accounts for all known liabilities. The value of current assets, loans and advances have a value on realisation in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet, unless otherwise stated.

NOTE `31`:

The Company has one segment of activity namely "Pharmaceuticals".

NOTE `32`:

In view of the requirements of Schedule II of the Companies Act 2013 ("Act"), depreciation for the year has been provided based on the lives prescribed under the schedule II.



For Medicamen Organics Ltd.

Director

Director

NOTE '33':

Related party disclosure as required by AS-18: Related Party Disclosures' notified by the Companies (Accounting Standard) Rules, 2006 are given below :

Name and Relationships of the Related Parties:

- (i) **Associate Concern**
 - (a) Red Line Healthcare.
 - (b) Red Line Healthcare Pvt Ltd.
- (ii) **Key Management Personnel**
 - (a) Ms. Ritu Gupta
 - (b) Sri Bal Kishan Gupta
 - (c) Sri Ashutosh Gupta
 - (d) Sri Hukam Chand Sharma

(Amount in Rupees)

Transactions with Related Parties	Enterprises over which key managerial person can exercise significant influence	Key Management Personnel
<u>Income</u>		
Sales of Material/Goods/ Others	- (-)	- (-)
<u>Expenditure</u>		
Purchase of Material	- (-)	- (-)
Rent	- (-)	- (-)
Remuneration		
1. Bal Kishan Gupta	- (-)	10,24,575 (9,86,881)
2. Ritu Gupta	- (-)	7,68,421 (7,57,770)
3. Ashutosh Gupta	- (-)	7,15,122 (7,30,226)
4. Hukam Chand Sharma	- (-)	19,80,000 (19,80,000)
O/S Receivables as on 31.03.2021	- (-)	-----



For MEDICAMEN ORGANICS LTD.

[Signature]
Director

For MEDICAMEN ORGANICS LTD.

[Signature]
Director

NOTE `34`:

The company has not during the year Capitalized which is shown as capital work in progress as on 31st, Mar ,2021,

NOTE `35`:

Previous Year's figures have been regrouped or recast wherever considered necessary.

As per our report of even date attached

For **ASHOK SHARMA & ASSOCIATES,**

Chartered Accountants

(Aditya Choudhary)

Partner

M. No – 528486


UDIN : 22528486AAAAAX2754

Place- New Delhi

Date- 26-11-2021

For **MEDICAMEN ORGANICS LTD.**

For Medicamen Organics Ltd.



Director

Director

DIN:00032772



Director

Director

DIN:00039995